Elutia Total Liabilities 2019-2025 | ELUT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Elutia total liabilities from 2019 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Elutia total liabilities from 2019 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$237.5B
Amgen (AMGN)	$162B
Gilead Sciences (GILD)	$142.8B
Vertex Pharmaceuticals (VRTX)	$120.5B
Bristol Myers Squibb (BMY)	$93.6B
CSL (CSLLY)	$84.5B
GSK (GSK)	$79.6B
Regeneron Pharmaceuticals (REGN)	$59.9B
Alnylam Pharmaceuticals (ALNY)	$44.3B
Argenex SE (ARGX)	$36.7B
BioNTech SE (BNTX)	$26.5B
Royalty Pharma (RPRX)	$20.9B
Insmed (INSM)	$20B
Biogen (BIIB)	$18.6B
Illumina (ILMN)	$16.9B
Incyte (INCY)	$15B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14.3B
Moderna (MRNA)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.3B
QIAGEN (QGEN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.2B
Exelixis (EXEL)	$9.9B
Bio-Techne Corp (TECH)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Exact Sciences (EXAS)	$8.8B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.4B